TABLE 1.

The SWOT analysis of using scaffolds based on RNA-gene therapy.

Strengths	Weakness
• Easily to introduce into cells with high efficiency.	• Cells might not be transfectable.
• Can be rapidly produced in the laboratory.	• Non-renewable resource.
	• Virus-mediated toxic effects.
• Cost efficient.	• The uncertainty of the scaffold degradation rate may affect the efficacy of the RNAs.
• Chemical modification can be used to reduce the off-target effect.
• May have a long-time effect.	• RNAs release limitation due to the strong interaction between scaffolds and the vectors.
• Scaffolds can protect RNA complexes from endogenous RNases.
• The local RNA delivery into the site of interest may use to avoid unwanted release in other sites.	• Regulation policies may cause a delay to get clinical trials approvals.
Opportunities	Threats
• A new sector in the market to access that provides long-term revenue.	• Long-time follow-up is required to ensure the safety and efficacy of therapy.
• A collaboration between the digital market based on artificial intelligence (AI) and the currently available data may accelerate RNA treatment development.	• Pre- or post-immune reactivity may limit the clinical trials.
• Merge the field of personalized medicine and the gene therapy which targets the oligonucleotide of an individual’s genotype may become applicable for gene silencing and directing the gene-editing case.	• More studies are necessary to find the optimal RNA sequence to use for treatment.
	• Biosimilar competition will need to demonstrate the efficacy of new therapy comparing to the traditional therapies.
	• Significant investments are required to cover all the expenses needed for RNA-based therapy manufacturing.